The Department of Health and Human Services Food and Drug Administration awarded a $9.4 million firm fixed price definitive contract to the University of Liverpool in Great Britain for characterization of severe coronavirus infection. Under the contract, the University of Liverpool will conduct research to characterize severe coronavirus infections over a five year period of performance ending in September 2025. No subcontractors or set aside designations were identified. The award provides funding for the University of Liverpool to support the FDA's ongoing efforts to understand coronavirus and potentially aid the development of medical countermeasures.
Generated 12/25/23, 1:14 AM